Tirzepatide
A dual GIP/GLP-1 receptor agonist approved by the FDA under brand names such as Mounjaro and Zepbound for specific medical indications.
What it is
Tirzepatide activates two incretin receptors at once — GLP-1 and GIP — which is why it is often described as a 'dual agonist.' It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Its SURPASS and SURMOUNT trial programs enrolled thousands of participants, and head-to-head data against semaglutide exists — a rarity in this space. As with every GLP-1-class drug, the trial evidence belongs to the approved products under medical supervision, not to whatever a non-pharmacy website ships in a vial.
What researchers have actually studied it for
Type 2 diabetes and chronic weight management in large registration trials, including head-to-head comparison against semaglutide.
How it works
Tirzepatide is a single 39-amino-acid peptide engineered to activate both the GIP and GLP-1 receptors. The GLP-1 arm slows gastric emptying and suppresses appetite; the GIP arm appears to amplify the metabolic effects and may improve how fat tissue handles nutrients — the precise contribution of GIP is still an active research question. A fatty-acid modification gives it week-long action.
Where it came from
Eli Lilly built tirzepatide on the 'twincretin' hypothesis — that adding GIP to GLP-1 signaling would beat either alone. FDA approved it for diabetes in 2022 and for weight management in 2023, after SURMOUNT-1 reported average weight reductions above 20% at the top dose — territory previously reserved for surgery.
What the research record actually contains
- SURPASS program: RCTs in type 2 diabetes, including superiority comparisons against semaglutide 1 mg on glycemic endpoints.
- SURMOUNT program: placebo-controlled obesity trials with ~20% average weight reduction at higher doses.
- SURMOUNT-5: open-label head-to-head against semaglutide in obesity — greater average weight loss with tirzepatide.
- Growing post-market record since 2022, plus an approval in obstructive sleep apnea with obesity.
What's known about risks
The profile echoes the GLP-1 class: gastrointestinal effects lead, concentrated during titration; gallbladder events, pancreatitis and the class thyroid warning appear on the label. Trial discontinuation rates were broadly comparable to semaglutide's. Long-term data is younger than semaglutide's simply because the drug is younger.
Where it stands legally
Prescription-only. The same shortage-era compounding story applies: compounded tirzepatide surged when brand supply lagged, and FDA has since pushed the market back toward the approved products as supply recovered. Non-prescription online vials are outside every lawful channel.
Worth asking a licensed provider
- 1.Given my history, does the GIP+GLP-1 mechanism offer anything over single-agonist options for me?
- 2.How will we handle dose escalation and GI side effects if they appear?
- 3.What does coverage look like — and if compounded is suggested, what makes it lawful now?
Tirzepatide FAQ
Head-to-head
Semaglutide vs. Tirzepatide
GLP-1 vs dual GIP/GLP-1 — how the two most prescribed weight-management peptides compare on evidence, average results, side effects and practical reality.
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.